ATE414697T1 - Nf-kb-inhibitoren - Google Patents

Nf-kb-inhibitoren

Info

Publication number
ATE414697T1
ATE414697T1 AT02800491T AT02800491T ATE414697T1 AT E414697 T1 ATE414697 T1 AT E414697T1 AT 02800491 T AT02800491 T AT 02800491T AT 02800491 T AT02800491 T AT 02800491T AT E414697 T1 ATE414697 T1 AT E414697T1
Authority
AT
Austria
Prior art keywords
kappab
inhibitors
diseases
activation
aminothiophene
Prior art date
Application number
AT02800491T
Other languages
English (en)
Inventor
Zehong Wan
Joelle BURGESS
James Callahan
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE414697T1 publication Critical patent/ATE414697T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
AT02800491T 2001-10-04 2002-10-04 Nf-kb-inhibitoren ATE414697T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32697601P 2001-10-04 2001-10-04

Publications (1)

Publication Number Publication Date
ATE414697T1 true ATE414697T1 (de) 2008-12-15

Family

ID=23274589

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02800491T ATE414697T1 (de) 2001-10-04 2002-10-04 Nf-kb-inhibitoren

Country Status (7)

Country Link
US (1) US7166639B2 (de)
EP (1) EP1448545B1 (de)
JP (1) JP2005506334A (de)
AT (1) ATE414697T1 (de)
DE (1) DE60229975D1 (de)
ES (1) ES2315430T3 (de)
WO (1) WO2003029242A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
CN101624391A (zh) * 2001-06-11 2010-01-13 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
TW200403991A (en) * 2002-04-11 2004-03-16 Smithkline Beecham Corp NF-κb inhibitors
AU2003249683A1 (en) * 2002-06-06 2003-12-22 Smithkline Beecham Corporation Nf-:b inhibitors
SE0202280D0 (sv) * 2002-07-19 2002-07-19 Astrazeneca Ab Novel compounds
SE0202279D0 (sv) * 2002-07-19 2002-07-19 Astrazeneca Ab Novel comppounds
JP2006512313A (ja) 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
US20060116419A1 (en) * 2002-12-06 2006-06-01 Callahan James F Nf-kb inhibitors
US7402608B2 (en) * 2002-12-10 2008-07-22 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
SE0300091D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300092D0 (sv) * 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
DE602004017478D1 (de) 2003-08-15 2008-12-11 Astrazeneca Ab Substituierte thiophene und deren verwendungen
US7119102B2 (en) * 2003-12-05 2006-10-10 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
BRPI0418351A (pt) * 2004-01-05 2007-05-08 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, métodos de limitar a proliferação celular em um humano ou animal, de tratamento de um humano ou animal sofrendo de cáncer, de tratamento de profilaxia de cáncer, de tratamento de um humano ou animal sofrendo de uma doença neoplásica, de tratamento de um humano ou animal sofrendo de uma doença prolifetativa de tratamento de cáncer, para o tratamento de infecções associadas com cáncer, para o tratamento profilático de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método de inibir a chk1 quinase, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo
GB0402809D0 (en) * 2004-02-09 2004-03-10 Glaxo Group Ltd Chemical compounds
AU2005233437A1 (en) * 2004-04-12 2005-10-27 Sankyo Company, Limited Thienopyridine derivatives
HRP20100678T1 (hr) 2005-03-29 2011-02-28 Icos Corporation Derivati heteroariluree korisni kao inhibitori chk1
BRPI0610283A2 (pt) * 2005-05-13 2010-10-19 Virochem Pharma Inc composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
EP1989203A2 (de) 2006-02-16 2008-11-12 Millennium Pharmaceuticals, Inc. Alpha-carboline und ihre verwendungen
CA2670260A1 (en) 2006-11-15 2008-05-22 Virochem Pharma Inc. Thiophene analogues for the treatment or prevention of flavivirus infections
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
KR20130097813A (ko) 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
JP2010006717A (ja) * 2008-06-24 2010-01-14 Kyorin Pharmaceut Co Ltd ジヒドロチエノ［２，３−ｅ］インダゾール化合物
CN102171204B (zh) 2008-10-02 2014-08-20 旭化成制药株式会社 8位取代异喹啉衍生物及其用途
US20100136096A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100135984A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100137247A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100137246A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100136094A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
US20100136095A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
WO2011077502A1 (ja) * 2009-12-21 2011-06-30 杏林製薬株式会社 ジヒドロチエノ［２，３－ｅ］インダゾール化合物
EP2520292A1 (de) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Verwendung von Spirangienen zur Behandlung oder Prävention von IL-8- oder IL-6-vermittelten Erkrankungen
US20150167097A1 (en) 2012-09-20 2015-06-18 Emory University CLASSIFIERS OF NF-kB PATHWAY ACTIVATION, DEVICES, AND METHODS OF USE THEREOF
JP7033789B2 (ja) 2016-06-29 2022-03-11 オトノミー，インク． トリグリセリド耳用製剤とその使用
EP3652542A1 (de) 2017-07-14 2020-05-20 Protea Biopharma N.V. Verfahren und vorrichtungen zur diagnose und / oder behandlung einer ermüdungserkrankung
ES3011633T3 (en) 2017-08-31 2025-04-07 Ahammune Biosciences Private Ltd Thiophene compounds, process for synthesis and use thereof for the treatment of autoimmune disorders
CN115161289B (zh) * 2022-03-14 2023-12-05 东南大学 一种用于炎症性疾病治疗的重组腺相关病毒及其构建方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468012A (en) * 1973-08-09 1977-03-23 Beecham Group Ltd 2-amino-3-carboxy-thiophene derivatives
DE4039734A1 (de) * 1990-12-13 1992-06-17 Basf Ag Substituierte 2-aminothiophene enthaltende herbizide mittel
US6274590B1 (en) * 1993-01-15 2001-08-14 G. D. Searle & Co. Method of treating skin related conditions
DE19642451A1 (de) * 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophencarbonsäureamide
CN1332943C (zh) * 1998-07-08 2007-08-22 萨诺费－阿文蒂斯德国有限公司 硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
EP1324759A4 (de) * 2000-10-12 2004-05-12 Smithkline Beecham Corp Nf--g(k)b inhibitoren
US6713638B2 (en) * 2001-05-18 2004-03-30 Joel M. Linden 2-amino-3-aroyl-4,5 alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors
CN101624391A (zh) * 2001-06-11 2010-01-13 病毒化学医药公司 用作黄病毒感染抗病毒剂的噻吩衍生物
SE0102617D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US6835745B2 (en) * 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
US7084178B2 (en) * 2003-11-26 2006-08-01 Bristol-Myers Squibb Company Antiamyloid phenylsulfonamides: N-cycloalkylcarboxamides derivatives

Also Published As

Publication number Publication date
EP1448545A1 (de) 2004-08-25
EP1448545A4 (de) 2005-01-12
DE60229975D1 (de) 2009-01-02
ES2315430T3 (es) 2009-04-01
US7166639B2 (en) 2007-01-23
WO2003029242A1 (en) 2003-04-10
JP2005506334A (ja) 2005-03-03
US20040192943A1 (en) 2004-09-30
EP1448545B1 (de) 2008-11-19

Similar Documents

Publication Publication Date Title
ATE414697T1 (de) Nf-kb-inhibitoren
PL1660507T5 (pl) Inhibitory proteazomu oraz sposoby ich stosowania
EA200300906A1 (ru) Новые спиротрициклические производные и их применение в качестве ингибиторов фосфодиэстеразы-7
SE0203752D0 (sv) New compounds
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
IL229124A0 (en) Inhibitors with a mutant form of kit
ATE387194T1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
TNSN05044A1 (en) Use of ikappab kinase inhibitors for the treatment of pain
ATE452642T1 (de) Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen
ATE382048T1 (de) Pyrazolopyrimdine als hemmstoffe cyclin abhängiger kinasen
ATE358673T1 (de) Nf-kb-inhibitoren
DE60322898D1 (de) Verwendung von isoflavonen zur förderung des schlankheitseffekts
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE60329326D1 (de) Tace inhibitoren
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
ATE353667T1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
WO2003086309A3 (en) NF-κB INHIBITORS
ATE300944T1 (de) Verwendung von substituierten distamycin- acryloylderivaten zur behandlung von tumoren die mit erhöhten glutathion-spiegeln zusammenhängen
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
ATE376416T1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
ATE534380T1 (de) Glepp-1-hemmer bei der behandlung von autoimmun- und/oder entzündungskrankheiten
ATE486598T1 (de) Kinase inhibitoren und deren verwendung
ATE548040T1 (de) Verwendung von vasopeptidase-inhibitoren zur behandlung von nephropathie
DE60335029D1 (de) Verwendung von thiazolbenzo-heterocyclenfür die behandlung von multipler sklerose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties